- Investing.com
Metrics to compare | SDZ | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSDZPeersSector | |
|---|---|---|---|---|
P/E Ratio | 62.2x | 29.1x | −0.3x | |
PEG Ratio | 0.33 | 0.03 | 0.00 | |
Price/Book | 4.5x | 4.1x | 2.6x | |
Price / LTM Sales | 3.4x | 4.0x | 3.1x | |
Upside (Analyst Target) | 0.9% | 10.9% | 49.0% | |
Fair Value Upside | Unlock | 8.8% | 6.3% | Unlock |
Sandoz Group AG develops, manufactures, and markets generic and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, supportive care, rare diseases, diabetes, immunology, endocrinology, neurology, osteoporosis, nephrology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company has a strategic collaboration with Shanghai Henlius Biotech, Inc. Sandoz Group AG was founded in 1886 and is headquartered in Basel, Switzerland.